HPLC, UHPLC
Oligonucleotide Biopolymers - Future Challenges for Chromatography
Mar 24 2011
Author: George Okaf, Daren S Levin and David Elder on behalf of Unassigned Independent Article
Synthetic Oligonucleotides as Therapeutic Medicines
Synthetic oligonucleotides are an exciting new class of biomolecules capable of treating many disorders, which are currently not amenable to existing drugs, including viral infections [1], respiratory disorders [2], cancers [3] and rare diseases [4]. Current interest has been largely fuelled by two key events: firstly, Fire and Mello’s Nobel-prize winning discovery of gene silencing by RNA interference (which helped to improve our understanding of the genetic basis of many diseases) [5]; and secondly, the regulatory approval of two oligonucleotide-based drugs, namely Vitravene® [6] (a 21-base single stranded antisense oligonucleotide approved by the FDA in 1998 for cytomegalovirus infections) and Macugen® [7] (a pegylated aptamer approved in 2005 for treating wet macular degeneration).
Digital Edition
Chromatography Today - Buyers' Guide 2022
October 2023
In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
ACS National Meeting - Fall 2024
Aug 18 2024 Denver, CO, USA
Sep 04 2024 Chiba, Tokyo, Japan